Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients

European Journal of Clinical Pharmacology

Volumn 49, Issue 1-2, 1995, Pages 21-26

  Thurig Ch ^a   Bohlen L ^a   Schneider, M ^a   de Courten, M ^a   Shaw, S G ^a   Weidmann, P ^a   Riesen, W ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Department of Neurosurgery   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitor; Hypertension; Insulin sensitivity; Lipoprotein metabolism; Lisinopril; physical fitness

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; LIPOPROTEIN; LISINOPRIL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS; LISINOPRIL; MALE; MIDDLE AGED;

EID: 0028866366     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/BF00192353     Document Type: Article

References (37)

1. Role of insulin resistance in human disease
2. Insulin resistance in essential hypertension
3. Insulin resistance, hyperinsulinemia and hypertension
4. Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in hypertension-prone humans
5. Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents
6. Epidemiology of coronary heart disease: the Framingham Study
7. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
8. Insulin resistance and risk factors for coronary heart disease
9. Carbohydrate metabolism in hypertension: influence of treatment
10. Collins R, Peto R, MacMahon S, et al. (1990) Blood pressure, stroke and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet:827–838
11. Antihypertensive agents, serum lipoproteins and glucose metabolism
12. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
13. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients
14. Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension
15. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension
16. Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril
17. Plasma glucose and insulin profiles in normal subjects ingesting diets of varying carbohydrate, fat, and protein content
18. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp
19. Modified protocols improve insulin sensitivity estimation using the minimal model
20. Determination of the anaerobic threshold by a noninvasive field test in runners
21. Insulin sensitivity and atrial natriuretic factor during beta-modulation with celiprolol in normal subjects
22. Age versus urinary sodium for judging renin, aldosterone and catecholamine levels. Studies in normal subjects and patients with essential hypertension
23. Manual of laboratory operations
24. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II
25. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension
26. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension
27. Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor
28. Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism
29. Metabolic effects of enalapril and nifedipine in diabetic hypertensives
30. The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension
31. Bak JF, Gerdes LU, Sorensen NS, Pedersen O (1992) Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 92:69S–72S
32. Verbesserte Glucoseeinstellung und Albuminurie bei Diabetikert unter ACE-Hemmer-Behandlung: eine Metaanalyse publizierter Studien aus den Jahren 1985 bis 1990
33. Exercise and hypertension. Maximizing the benefits in patients receiving drug therapy
34. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus
35. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes
36. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension
37. Lisinopril in the treatment of hypertension: a Canadian postmarketing surveillance study